Expanding the Evidence on the Safety and Efficiency of 2-Way Text Messaging-Based Telehealth for Voluntary Medical Male Circumcision Follow-up Compared With In-Person Reviews: Randomized Controlled Trial in Rural and Urban South Africa.
2-way texting
COVID-19
SMS text messaging–based telehealth
South Africa
digital health innovation in low- and middle-income countries
mHealth for quality improvement
male engagement in care
mobile health
mobile phone
voluntary medical male circumcision
Journal
Journal of medical Internet research
ISSN: 1438-8871
Titre abrégé: J Med Internet Res
Pays: Canada
ID NLM: 100959882
Informations de publication
Date de publication:
09 05 2023
09 05 2023
Historique:
received:
22
08
2022
accepted:
24
02
2023
revised:
22
12
2022
medline:
11
5
2023
pubmed:
9
5
2023
entrez:
9
5
2023
Statut:
epublish
Résumé
There is a dearth of high-quality evidence from digital health interventions in routine program settings in low- and middle-income countries. We previously conducted a randomized controlled trial (RCT) in Zimbabwe, demonstrating that 2-way texting (2wT) was safe and effective for follow-up after adult voluntary medical male circumcision (VMMC). To demonstrate the replicability of 2wT, we conducted a larger RCT in both urban and rural VMMC settings in South Africa to determine whether 2wT improves adverse event (AE) ascertainment and, therefore, the quality of follow-up after VMMC while reducing health care workers' workload. A prospective, unblinded, noninferiority RCT was conducted among adult participants who underwent VMMC with cell phones randomized in a 1:1 ratio between 2wT and control (routine care) in North West and Gauteng provinces. The 2wT participants responded to a daily SMS text message with in-person follow-up only if desired or an AE was suspected. The control group was requested to make in-person visits on postoperative days 2 and 7 as per national VMMC guidelines. All participants were asked to return on postoperative day 14 for study-specific review. Safety (cumulative AEs ≤day 14 visit) and workload (number of in-person follow-up visits) were compared. Differences in cumulative AEs were calculated between groups. Noninferiority was prespecified with a margin of -0.25%. The Manning score method was used to calculate 95% CIs. The study was conducted between June 7, 2021, and February 21, 2022. In total, 1084 men were enrolled (2wT: n=547, 50.5%, control: n=537, 49.5%), with near-equal proportions of rural and urban participants. Cumulative AEs were identified in 2.3% (95% CI 1.3-4.1) of 2wT participants and 1.0% (95% CI 0.4-2.3) of control participants, demonstrating noninferiority (1-sided 95% CI -0.09 to ∞). Among the 2wT participants, 11 AEs (9 moderate and 2 severe) were identified, compared with 5 AEs (all moderate) among the control participants-a nonsignificant difference in AE rates (P=.13). The 2wT participants attended 0.22 visits, and the control participants attended 1.34 visits-a significant reduction in follow-up visit workload (P<.001). The 2wT approach reduced unnecessary postoperative visits by 84.8%. Daily response rates ranged from 86% on day 3 to 74% on day 13. Among the 2wT participants, 94% (514/547) responded to ≥1 daily SMS text messages over 13 days. Across rural and urban contexts in South Africa, 2wT was noninferior to routine in-person visits for AE ascertainment, demonstrating 2wT safety. The 2wT approach also significantly reduced the follow-up visit workload, improving efficiency. These results strongly suggest that 2wT provides quality VMMC follow-up and should be adopted at scale. Adaptation of the 2wT telehealth approach to other acute follow-up care contexts could extend these gains beyond VMMC. ClinicalTrials.gov NCT04327271; https://www.clinicaltrials.gov/ct2/show/NCT04327271.
Sections du résumé
BACKGROUND
There is a dearth of high-quality evidence from digital health interventions in routine program settings in low- and middle-income countries. We previously conducted a randomized controlled trial (RCT) in Zimbabwe, demonstrating that 2-way texting (2wT) was safe and effective for follow-up after adult voluntary medical male circumcision (VMMC).
OBJECTIVE
To demonstrate the replicability of 2wT, we conducted a larger RCT in both urban and rural VMMC settings in South Africa to determine whether 2wT improves adverse event (AE) ascertainment and, therefore, the quality of follow-up after VMMC while reducing health care workers' workload.
METHODS
A prospective, unblinded, noninferiority RCT was conducted among adult participants who underwent VMMC with cell phones randomized in a 1:1 ratio between 2wT and control (routine care) in North West and Gauteng provinces. The 2wT participants responded to a daily SMS text message with in-person follow-up only if desired or an AE was suspected. The control group was requested to make in-person visits on postoperative days 2 and 7 as per national VMMC guidelines. All participants were asked to return on postoperative day 14 for study-specific review. Safety (cumulative AEs ≤day 14 visit) and workload (number of in-person follow-up visits) were compared. Differences in cumulative AEs were calculated between groups. Noninferiority was prespecified with a margin of -0.25%. The Manning score method was used to calculate 95% CIs.
RESULTS
The study was conducted between June 7, 2021, and February 21, 2022. In total, 1084 men were enrolled (2wT: n=547, 50.5%, control: n=537, 49.5%), with near-equal proportions of rural and urban participants. Cumulative AEs were identified in 2.3% (95% CI 1.3-4.1) of 2wT participants and 1.0% (95% CI 0.4-2.3) of control participants, demonstrating noninferiority (1-sided 95% CI -0.09 to ∞). Among the 2wT participants, 11 AEs (9 moderate and 2 severe) were identified, compared with 5 AEs (all moderate) among the control participants-a nonsignificant difference in AE rates (P=.13). The 2wT participants attended 0.22 visits, and the control participants attended 1.34 visits-a significant reduction in follow-up visit workload (P<.001). The 2wT approach reduced unnecessary postoperative visits by 84.8%. Daily response rates ranged from 86% on day 3 to 74% on day 13. Among the 2wT participants, 94% (514/547) responded to ≥1 daily SMS text messages over 13 days.
CONCLUSIONS
Across rural and urban contexts in South Africa, 2wT was noninferior to routine in-person visits for AE ascertainment, demonstrating 2wT safety. The 2wT approach also significantly reduced the follow-up visit workload, improving efficiency. These results strongly suggest that 2wT provides quality VMMC follow-up and should be adopted at scale. Adaptation of the 2wT telehealth approach to other acute follow-up care contexts could extend these gains beyond VMMC.
TRIAL REGISTRATION
ClinicalTrials.gov NCT04327271; https://www.clinicaltrials.gov/ct2/show/NCT04327271.
Identifiants
pubmed: 37159245
pii: v25i1e42111
doi: 10.2196/42111
pmc: PMC10206620
doi:
Banques de données
ClinicalTrials.gov
['NCT04327271']
Types de publication
Equivalence Trial
Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
e42111Subventions
Organisme : NINR NIH HHS
ID : R01 NR019229
Pays : United States
Informations de copyright
©Caryl Feldacker, Jacqueline Pienaar, Beatrice Wasunna, Felex Ndebele, Calsile Khumalo, Sarah Day, Hannock Tweya, Femi Oni, Maria Sardini, Binod Adhikary, Evelyn Waweru, Mourice Barasa Wafula, Anna Dixon, Krishna Jafa, Yanfang Su, Kenneth Sherr, Geoffrey Setswe. Originally published in the Journal of Medical Internet Research (https://www.jmir.org), 09.05.2023.
Références
Front Digit Health. 2022 Jun 03;4:876957
pubmed: 35754461
J Am Med Inform Assoc. 2019 Aug 1;26(8-9):884-890
pubmed: 31188438
Glob Policy. 2021 Jul;12(Suppl 6):107-109
pubmed: 34230840
JMIR Mhealth Uhealth. 2019 Aug 19;7(8):e13309
pubmed: 31429414
Lancet Digit Health. 2020 Apr;2(4):e160-e162
pubmed: 33328076
NPJ Digit Med. 2020 Aug 27;3:110
pubmed: 32904379
J Glob Health. 2020 Dec;10(2):020396
pubmed: 33274059
Global Health. 2021 Jul 6;17(1):77
pubmed: 34229699
Pan Afr Med J. 2020 May 18;35(Suppl 2):38
pubmed: 33623563
J Int AIDS Soc. 2014 Nov 17;17:19275
pubmed: 25406951
J Int AIDS Soc. 2019 Jul;22(7):e25369
pubmed: 31368235
Hum Behav Emerg Technol. 2021 Dec;3(5):843-853
pubmed: 34901772
AIDS. 2012 Mar 13;26(5):559-66
pubmed: 22112602
Digit Health. 2020 Jul 20;6:2055207620942360
pubmed: 32742717
Soc Sci Med. 2018 Feb;198:139-147
pubmed: 29335160
Curr HIV/AIDS Rep. 2022 Dec;19(6):508-515
pubmed: 36348185
Stud Health Technol Inform. 2020 Jun 23;271:85-92
pubmed: 32578546
BMJ Open. 2018 Sep 1;8(8):e021835
pubmed: 30173159
J Int AIDS Soc. 2017 Feb 20;19(1):21394
pubmed: 28362066
BMJ Glob Health. 2018 Apr 24;3(Suppl 2):e000626
pubmed: 29713512
Mhealth. 2020 Oct 05;6:43
pubmed: 33437839
JMIR Mhealth Uhealth. 2017 Oct 06;5(10):e136
pubmed: 28986340
PLoS One. 2019 Jun 10;14(6):e0218137
pubmed: 31181096
PLoS One. 2018 Sep 21;13(9):e0204091
pubmed: 30240417
AIDS Care. 2019 Nov;31(11):1435-1446
pubmed: 30909724
PLoS One. 2020 Sep 30;15(9):e0239915
pubmed: 32997710
NPJ Digit Med. 2021 Feb 26;4(1):40
pubmed: 33637833
PLoS One. 2021 Aug 17;16(8):e0253960
pubmed: 34403409
JMIR Mhealth Uhealth. 2018 Jan 17;6(1):e23
pubmed: 29343463
BMJ Glob Health. 2021 Nov;6(11):
pubmed: 34815242
PLoS One. 2016 Oct 26;11(10):e0164147
pubmed: 27783635
AIDS Behav. 2022 Feb;26(2):457-469
pubmed: 34427813
PLoS One. 2018 Sep 7;13(9):e0203292
pubmed: 30192816
PLoS One. 2022 Apr 14;17(4):e0266717
pubmed: 35421134
Glob Health Sci Pract. 2018 Oct 10;6(Suppl 1):S5-S17
pubmed: 30305335
NPJ Digit Med. 2020 Sep 18;3:120
pubmed: 33015373
PLoS One. 2014 May 06;9(5):e80577
pubmed: 24801209
PLOS Digit Health. 2022 Jun 15;1(6):e0000066
pubmed: 36812548
Ann Med Surg (Lond). 2021 Jun;66:102378
pubmed: 33996071
PLoS One. 2021 Oct 20;16(10):e0258611
pubmed: 34669709
Global Health. 2018 Nov 3;14(1):103
pubmed: 30390686
J Med Internet Res. 2019 Oct 9;21(10):e13263
pubmed: 31593543
JMIR Form Res. 2023 Mar 22;7:e44122
pubmed: 36947127
Annu Rev Public Health. 2022 Apr 5;43:525-539
pubmed: 34648368
Digit Health. 2021 Apr 19;7:20552076211009396
pubmed: 33959378
J Acquir Immune Defic Syndr. 2020 Jan 1;83(1):16-23
pubmed: 31809358
Inf Technol Dev. 2019 Sep 29;26(3):477-505
pubmed: 32982007
Mhealth. 2021 Apr 20;7:38
pubmed: 33898607
Smart Health (Amst). 2021 Jul;21:100207
pubmed: 36570120
J Acquir Immune Defic Syndr. 2021 Oct 1;88(2):173-180
pubmed: 34173789
BMC Health Serv Res. 2019 Nov 21;19(1):855
pubmed: 31752838
PLoS One. 2020 Jun 16;15(6):e0233234
pubmed: 32544161
Pan Afr Med J. 2013 Jul 15;15:100
pubmed: 24198894
Glob Health Sci Pract. 2014 Jan 09;2(1):93-102
pubmed: 25276565
Trials. 2019 Jul 23;20(1):451
pubmed: 31337414
J Telemed Telecare. 2021 Dec 30;:1357633X211070726
pubmed: 34967240
AIDS Patient Care STDS. 2020 Feb;34(2):59-71
pubmed: 32049555
Glob Health Sci Pract. 2020 Mar 31;8(1):55-67
pubmed: 32139420
Int J Med Inform. 2021 Jul;151:104467
pubmed: 33915421
J Public Health Policy. 2016 Nov;37(Suppl 2):201-212
pubmed: 27899795
Glob Health J. 2022 Jun;6(2):102-113
pubmed: 35282399